Table 1.
Patient Demographics
| Patient Demographics | Overall (n=1,285) | Commercial (n=1,011) | Medicaid (n=89) | Medicare (n=185) | p-value2 |
|---|---|---|---|---|---|
| Age at Surgery1 | 50 (44, 57) | 49 (44, 55) | 46 (41, 54) | 63 957, 66) | <0.001 |
| Race | <0.001 | ||||
| White | 886 (69%) | 708 (70%) | 44 (49%) | 134 (72%) | |
| Asian | 111 (8.6%) | 95 (9.4%) | 7 (7.9%) | 9 (4.9%) | |
| Black | 164 (13%) | 121 (12%) | 17 (19%) | 26 (14%) | |
| Other | 124 (9.6%) | 87 (8.6%) | 21 (24%) | 16 (8.6%) | |
| Ethnicity | 0.001 | ||||
| Not Hispanic | 1,106 (86%) | 884 (87%) | 63 (71%) | 159 (86%) | |
| Hispanic | 132 (10%) | 92 (9.1%) | 21 (24%) | 19 (10%) | |
| Unknown | 47 (3.7%) | 35 (3.5%) | 5 (5.6%) | 7 (3.8%) | |
| Marital Status | <0.001 | ||||
| Married | 941 (73%) | 773 (76%) | 43 (48%) | 125 (68%) | |
| Separated | 121 (9.4%) | 78 (7.7%) | 16 (18%) | 27 (15%) | |
| Single | 223 (17%) | 160 (16%) | 30 (34%) | 33 (18%) | |
| Body Mass Index (BMI)1 | 26.2 (23.4, 29.7) | 26.2 (23.4, 29.7) | 26.5 (23.9, 29.8) | 26.9 (23.3, 29.8) | 0.8 |
| Smoking Status | 0.024 | ||||
| Never | 948 (74%) | 757 (75%) | 68 (76%) | 123 (66%) | |
| Current | 32 (2.5%) | 23 (2.3%) | 5 (5.6%) | 4 (2.2%) | |
| Former | 305 (24%) | 231 (23%) | 16 (18%) | 58 (31%) | |
| Median household income | 96,606 (73,514, 127,680) | 102,763 (77,044, 130,121) | 66,332 (56,870, 99,572) | 87,397 (69,353, 1223,492) | <0.001 |
| History of psychiatric comorbidities | 718 (56%) | 547 (54%) | 58 (65%) | 113 (61%) | 0.04 |
| Chemotherapy | |||||
| Adjuvant/Neoadjuvant | 998 (78%) | 777 (77%) | 78 (88%) | 143 (77%) | 0.064 |
| Radiation | |||||
| Adjuvant/Neoadjuvant | 87 (6.8%) | 67 (6.6%) | 8 (9.0%) | 12 (6.5%) | 0.7 |
| Donor Site Laterality | 0.007 | ||||
| Bilateral | 628 (49%) | 517 (51%) | 35 (39%) | 76 (41%) | |
| Unilateral | 657 (51%) | 494 (49%) | 54 (61%) | 109 (59%) | |
| Prophylactic | 0.012 | ||||
| None | 855 (67%) | 650 (64%) | 69 (78%) | 136 (74%) | |
| Contralateral prophylactic | 391 (30%) | 326 (32%) | 20 (22%) | 45 (24%) | |
| Bilateral prophylactic | 39 (3.0%) | 35 (3.5%) | 0 (0%) | 4 (2.2%) | |
| Axillary lymph node biopsy | 763 (59%) | 611 (60%) | 63 (71%) | 89 (48%) | <0.001 |
| Postoperative length of stay (LOS) in days1 | 3 (3,5) | 3 (3,5) | 4 (3,6) | 4 (3,6) | 0.2 |
1
Median (IQR); n(%),
2
Kruskal-Wallis rank sum test; Fischer’s Exact Test for Count Data with simulated p-value